
LCTX Stock Forecast & Price Target
LCTX Analyst Ratings
Bulls say
Lineage Cell Therapeutics is poised for success due to its strong financial results, driven by significant revenue growth and effective cost management strategies. Additionally, the company's diverse and promising pipeline, particularly with OpRegen, positions it well for continued growth and expansion in various therapeutic areas. Despite some potential risks and challenges, the company's solid partnerships, experienced management team, and advanced technologies make it a promising investment for the future.
Bears say
Lineage Cell Therapeutics is a clinical-stage biotechnology company with a proprietary, in-house cell-based manufacturing platform and promising therapies in its pipeline targeting degenerative diseases such as geographic atrophy, spinal cord injury, and sensorineural hearing loss. However, the company faces significant risks including regulatory and financial challenges, competition in the market, potential legal and intellectual property disputes, and uncertainties in gaining market share. This, combined with the lack of demonstrated visual benefit in current therapies for geographic atrophy, is why the author holds a negative outlook on the company's stock.
This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LCTX Analyst Forecast & Price Prediction
Start investing in LCTX
Order type
Buy in
Order amount
Est. shares
0 shares